Document:

EX-10.8

 Exhibit 10.8 
 May 22, 2013 
 Dear Matt: 
 Evoke Pharma, Inc. (the “Company”) values your future contributions. This letter agreement amends and restates (the “Amended and Restated Letter Agreement”)
a letter agreement entered into by you with the Company on March 28, 2012, and describes a retention program the Company has established for each of its employees. 
 1. Retention Events. Upon the first to occur of (a) a Change of Control (as defined below), or (b) an Equity Financing (as defined below) (each such event, a “Retention
Event”), you will be eligible to receive a payment(s) in the amount of $130,000.00 (the “Retention Amount”). In the event the Retention Event is a Change of Control, the Retention Amount will be paid to you in
cash on the closing date of such Change of Control to recognize the support required to assist in transferring trade secrets and ongoing project management beyond the date of termination. In the event the Retention Event is an Equity Financing, the
Retention Amount will be paid to you in cash in 3 equal installments over the 3 months following the consummation of the Equity Financing to ensure a heightened level of support required to accelerate corporate development. Subject to paragraph 2
below, your eligibility for receipt of the foregoing payment(s) is contingent upon your continued employment through the applicable payment date(s). For purposes of this Amended and Restated Letter Agreement, the term “Change of
Control” shall have the meaning given to such term in your Amended and Restated Employment Agreement dated as of August 12, 2008, with the Company (the “Employment Agreement”) as in effect on the date hereof. For
purposes of this Amended and Restated Letter Agreement, the term “Equity Financing” shall mean the consummation of a public or private equity financing in which investors purchase shares of the Company’s
common or preferred stock. 
 2. Effect of Termination of Employment. If you voluntarily terminate your employment with
the Company without Good Reason (as defined below) or your employment terminates as a result of your death or disability (which for these purposes will mean that you are eligible for benefits under the Company’s long-term disability plan) or if
the Company terminates your employment for Cause (as defined below), in each case prior to the date on which you have received the full Retention Amount, then you will forfeit any right you may have to receive any unpaid portion of the Retention
Amount under this Amended and Restated Letter Agreement. For purposes of this Amended and Restated Letter Agreement, the terms “Cause” and “Good Reason” shall have the meanings given to such terms in
the Employment Agreement (provided that clauses (vi) and (vii) of the definition of Good Reason shall not apply for purposes of this Amended and Restated Letter Agreement, you must give the Company notice of the initial occurrence of the event(s)
giving rise to Good Reason within thirty days after such occurrence and your resignation for Good Reason must occur within ninety days following the initial occurrence of the event giving rise to Good Reason). 

If, however, the Company terminates your employment without Cause or you resign for Good Reason prior to the date on which you have
received the full Retention Amount, and without regard to whether a Retention Event has occurred prior to the date of termination, then you will be entitled to receive any unpaid portion of the Retention Amount on the date that is sixty days
following your date of termination. As a condition to your receipt of the unpaid portion of the Retention Amount following your termination of employment without Cause or resignation for Good Reason, you will be required to execute a release (the
“Release”) in a form acceptable to the Company. Such Release shall specifically relate to all of your rights and claims in existence at the time of such execution and shall confirm your obligations under the Company’s
standard form of proprietary information and inventions agreement. It is understood that, as specified in the applicable Release, you 

 
will have a certain number of calendar days to consider whether to execute such Release, and you may revoke such Release within seven calendar days after execution. In the
event your Release does not become effective within the sixty day period following your date of termination, you will forfeit your right to receive the unpaid portion of the Retention Amount. 

The unpaid portion of the Retention Amount will be paid to you in cash within five days following the effective date of your Release.

 3. Relationship to Other Compensation. The Retention Amount described herein is independent of all other compensation.
You will also remain eligible for all benefits under the Employment Agreement. 
 4. Tax and Other Deductions. The
Retention Amount will be paid, less federal, state and local taxes required to be withheld by the Company. 
 5.
Employment at Will. This Amended and Restated Letter Agreement does not affect your employment relationship with the Company; that is, employment with the Company remains at-will unless otherwise expressly agreed in a separate written
contract between you and the Company. 
 6. Section 409A of the Internal Revenue Code. To the maximum extent
permitted by applicable law, the amounts payable pursuant to this Amended and Restated Letter Agreement shall be made in reliance upon Treasury Regulation Section 1.409A-1(b)(4) (with respect to short-term deferrals). To the extent the Retention
Amount payable under this Amended and Restated Letter Agreement are subject to Section 409A of the Internal Revenue Code, this Amended and Restated Letter Agreement shall be interpreted, construed and administered in a manner that satisfies the
requirements of Sections 409A(a)(2), (3) and (4) of the Internal Revenue Code and the Treasury Regulations thereunder. 
 7.
Miscellaneous. This Amended and Restated Letter Agreement shall be binding upon and inure to the benefit of the successors of the Company. This Amended and Restated Letter Agreement will not give any rights or remedies to any person other
than the undersigned employee and the Company and its successors. This Amended and Restated Letter Agreement will be governed by the laws of the State of California, excluding any that mandate the use of another jurisdiction’s laws. This
Amended and Restated Letter Agreement may only be amended with the written consent of the Chairman of the Board of the Company and you. You shall have no rights under this Amended and Restated Letter Agreement other than as an unsecured general
creditor of the Company. 
 Sincerely, 
  

	
	 /s/ David A. Gonyer

	 Print Name: David A. Gonyer

	 Title: Chief Executive Officer

 I acknowledge that I understand and agree to abide by the provisions set forth in the above stated Amended and Restated
Letter Agreement. 

	
	 /s/ Matt D’Onofrio

			
	Print Name:  	 	 Matt D’OnofrioEX 10.9

 Exhibit 10.9 
 EVOKE PHARMA, INC. 
 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

 Non-employee members of the board of directors (the “Board”) of Evoke Pharma, Inc. (the
“Company”) shall be eligible to receive cash and equity compensation commencing on the date immediately preceding the first date upon which the Company is subject to the reporting requirements of Section 13 or 15(d)(2)
of the Securities Exchange Act of 1934, as amended (the “Public Trading Date”), as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation
described in this Policy shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a
“Non-Employee Director”) who may be eligible to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company. This
Policy shall remain in effect until it is revised or rescinded by further action of the Board. The terms and conditions of this Policy shall supersede any prior cash or equity compensation arrangements between the Company and its Non-Employee
Directors. 
 1. Cash Compensation. 
 (a) Annual Retainers. Each Non-Employee Director shall be eligible to receive an annual retainer of $17,500 for service on the Board. In addition, a Non-Employee Director shall receive the
following additional annual retainers, as applicable: 
 (i) Chairperson of the Board. A Non-Employee Director serving as
Chairperson of the Board shall receive an additional annual retainer of $17,500 for such service. 
 (ii) Chairperson of the
Audit Committee. A Non-Employee Director serving as Chairperson of the Audit Committee shall receive an additional annual retainer of $7,500 for such service. 
 (iii) Member of the Audit Committee. A Non-Employee Director serving as a member of the Audit Committee (other than the Chairperson) shall receive an additional annual retainer of $3,750 for such
service. 
 (iv) Chairperson of the Compensation Committee. A Non-Employee Director serving as Chairperson of the
Compensation Committee shall receive an additional annual retainer of $5,000 for such service. 
 (v) Member of the
Compensation Committee. A Non-Employee Director serving as a member of the Compensation Committee (other than the Chairperson) shall receive an additional annual retainer of $2,500 for such service. 

(vi) Chairperson of the Nominating and Corporate Governance Committee. A Non-Employee Director serving as Chairperson of the
Nominating and Corporate Governance Committee shall receive an additional annual retainer of $3,500 for such service. 
 (vii)
Member of the Nominating and Corporate Governance Committee. A Non-Employee Director serving as a member of the Nominating and Corporate Governance Committee (other than the Chairperson) shall receive an additional annual retainer of $1,750
for such service. 

 (b) Payment of Retainers. The annual retainers described in Section 1(a) shall
be earned on a quarterly basis based on a calendar quarter and shall be paid by the Company in arrears not later than the fifth business day following the end of each calendar quarter. In the event a Non-Employee Director does not serve as a
Non-Employee Director, or in the applicable positions described in Section 1(a), for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter actually served as a
Non-Employee Director, or in such positions, as applicable. 
 2. Equity Compensation. Non-Employee Directors shall be
granted the equity awards described below. The awards described below shall be granted under and shall be subject to the terms and provisions of the 2013 Equity Incentive Award Plan (the “Equity Plan”) and shall be granted
subject to the execution and delivery of award agreements, including attached exhibits, in substantially the same forms previously approved by the Board, setting forth the vesting schedule applicable to such awards and such other terms as may be
required by the Equity Plan. 
 (a) Initial Awards. A person who is serving as a Non-Employee Director on the date
immediately preceding the Public Trading Date shall be eligible to receive a stock option to purchase 30,000 shares of the Company’s common stock on such date. In addition, a person who is initially elected or appointed to the Board following
the Public Trading Date, and who is a Non-Employee Director at the time of such initial election or appointment, shall be eligible to receive a stock option to purchase 30,000 shares of the Company’s common stock on the date of such initial
election or appointment. The awards described in this Section 2(a) shall be referred to as “Initial Awards.” No Non-Employee Director shall be granted more than one Initial Award. 

(b) Subsequent Awards. A person who is a Non-Employee Director immediately following each annual meeting of the Company’s
stockholders after the Public Trading Date and who will continue to serve as a Non-Employee Director immediately following such annual meeting shall be automatically granted an option to purchase 15,000 shares of the Company’s common stock on
the date of each such annual meeting. The awards described in this Section 2(b) shall be referred to as “Subsequent Awards.” For the avoidance of doubt, a Non-Employee Director elected for the first time to the Board at
an annual meeting of the Company’s stockholders shall only receive an Initial Award in connection with such election, and shall not receive any Subsequent Award on the date of such meeting as well. 

(c) Termination of Employment of Employee Directors. Members of the Board who are employees of the Company or any parent or
subsidiary of the Company who subsequently terminate their employment with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Award pursuant to Section 2(a) above, but to the extent that
they are otherwise eligible, will be eligible to receive, after termination from employment with the Company and any parent or subsidiary of the Company, Subsequent Awards as described in Section 2(b) above. 

(d) Terms of Awards Granted to Non-Employee Directors. 
 (i) Purchase Price. The per share exercise price of each option granted to a Non-Employee Director shall equal 100% of the Fair Market Value (as defined in the Equity Plan) of a share of common
stock on the date the option is granted; provided, however, that the per share exercise price of each Initial Award granted to a Non-Employee Director on the date immediately preceding the Public Trading Date shall equal the initial public offering
price per share of the Company’s common stock. 

 (ii) Vesting. Each Initial Award shall vest and become exercisable in three equal
annual installments over the three year period following the date of grant, subject to the Non-Employee Director continuing in service on the Board through each such vesting date. Each Subsequent Award shall vest and/or become exercisable on the
one-year anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Board through each such vesting date. All of a Non-Employee Director’s Initial Awards and Subsequent Awards shall vest in full upon the
occurrence of a Change in Control (as defined in the Equity Plan). 
 (iii) Term. The term of each stock option granted
to a Non-Employee Director shall be ten years from the date the option is granted. Upon a Non-Employee Director’s termination of membership on the Board for any reason, his or her stock options granted under this Policy shall remain exercisable
for twelve months following his or her termination of membership on the Board (or such longer period as the Board may determine in its discretion on or after the date of grant of such stock options).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}]]